AI Article Synopsis
- The study focused on hepatitis B virus (HBV) infection rates among military personnel in eastern China to inform prevention strategies.
- A total of 17,894 individuals (15,508 soldiers and 2,386 officers) were analyzed, revealing low HBsAg positive rates (0.44% in soldiers and 1.72% in officers), with a higher prevalence of low-level HBsAg among soldiers.
- Notable differences were found in HBV markers and DNA extraction methods, highlighting the need for improved screening and prevention measures in the military context.
Article Abstract
This study aimed to investigate hepatitis B virus (HBV) infection in military personnel in eastern China, which will provide a basis for the prevention of HBV infection.A total of 15,508 soldiers and 2386 officers were recruited from military camps in eastern China. The markers, deoxyribonucleic acid, serotypes, and genotypes of HBV in serum were detected and analyzed.Hepatitis B surface antigen (HBsAg) positive rate was 0.44% in soldiers, in whom the low-level HBsAg accounted for 88.24%. The HBsAg positive rate was 1.72% in officers in whom the low-level HBsAg accounted for 12.20%. There were significant differences in the prevalence of high-level and low-level HBsAg, HBV serotypes, HBV DNA positive rate, and mean log HBV DNA between officers and soldiers (P < .05). Compared with the conventional method for HBV DNA extraction, the enrichment method for HBV DNA extraction could significantly improve the positive rate and quantification of HBV DNA by real-time fluorescence quantitative polymerase chain reaction (P < .05). Sequencing of S gene in HBV was used for the determination of serotype and genotype of HBV. The sequencing success rate was significantly different between soldiers and officers (P < .05) as well as between high-level HBsAg group and low-level HBsAg group (P < .05). Significant difference was also observed in the genotype distribution between soldiers and officers (P < .05).HBV infection displays a low prevalence and a low epidemic state, and the prevalence of low-level HBsAg is higher in soldiers. We should pay attention to improve the quality of conscription examination as well as emphasize the surveillance, prevention, and protection of HBV infection in military officers.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6160064 | PMC |
| http://dx.doi.org/10.1097/MD.0000000000012201 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Augmented epigenetic repression of hepatitis B virus covalently closed circular DNA by interferon-α and small-interfering RNA synergy.
mBio
December 2024
Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), Research Unit of Cure of Chronic Hepatitis B Virus Infection (CAMS), Shanghai Frontiers Science Center of Pathogenic Microbes and Infection, School of Basic Medical Sciences, Shanghai Medical College Fudan University, Shanghai, China.
Unlabelled: The persistence of hepatitis B virus (HBV) covalently closed circular DNA (cccDNA) is a key obstacle for HBV cure. This study aims to comprehensively assess the effect of interferon (IFN) and small-interfering RNA (siRNA) combination on the cccDNA minichromosome. Utilizing both cell and mouse cccDNA models, we compared the inhibitory effects of IFNα, siRNA, and their combination on cccDNA activity and assessed its epigenetic state.
View Article and Find Full Text PDF[Analysis of the incidence of low viral load/low-level viremia and its associated factors in patients with HBV-related primary liver cancer].
Zhonghua Gan Zang Bing Za Zhi
October 2024
Center of Hepatology and Department of Infectious Disease, Jinling Hospital (General Hospital of Eastern Theater Command), Affiliated to School of Medicine, Nanjing University, Nanjing210002, China.
To retrospectively analyze the viral levels and associated factors in patients with hepatitis B virus (HBV)-related primary liver cancer (PHC) in real-world settings and further explore the correlation between low viral load (LVL) and/or low-level viremia (LLV) and PHC. Five hundred twenty-four cases with HBV-related PHC with complete pathologically confirmed data from 2013 to 2020 were included. Percentages (%) were used to express their viral load, antiviral (oral) status, patient compliance, presence or absence of cirrhosis, family history of liver cancer, and others.
View Article and Find Full Text PDFAn overview of occult hepatitis B infection (OBI) with emphasis on HBV vaccination.
Heliyon
September 2024
Medical Genetics Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Background: The prevalence of chronic hepatitis B virus (HBV) poses a significant threat to the lives of 257 million individuals globally, potentially resulting in severe outcomes such as liver cirrhosis or hepatocellular carcinoma. Among the existing preventive measures, yeast-derived vaccines have proven to be the most efficacious approach in combatting hepatitis B. Nonetheless, as scientific inquiries focus more on occult HBV infection (OBI) in vaccinated persons and the lingering risk of vertical transmission affecting 10-30 % of babies born to HBsAg-positive mothers, there is a growing apprehension regarding the inability of HBV vaccines to ensure complete immunity.
View Article and Find Full Text PDFHepatitis B Virus (HBV) remains a major global health challenge, with significant morbidity and mortality associated with chronic infections. This study examines the epidemiology, screening, and risk factors associated with HBV in Romania, focusing on a comprehensive national screening program, LIVE(RO)2, involving 320,000 individuals (majority of them considered vulnerable population). A questionnaire was used to collect information on the potential risk factors for HBV transmission.
View Article and Find Full Text PDFRisk factors related to low-level viraemia in chronic hepatitis B patients receiving entecavir treatment.
Front Cell Infect Microbiol
August 2024
Out-patient Department, Hospital of Beijing Information Science and Technology University, Beijing, China.
Article Synopsis
- About 20% of patients being treated for chronic hepatitis B experience low-level viraemia (LLV), leading to inflammation, fibrosis progression, and higher cancer risk.
- In a study of 1,653 patients treated with entecavir, factors like HBeAg positivity, high HBV DNA levels, and liver cirrhosis were found to be significantly linked to the development of LLV.
- The findings suggest that monitoring high HBV DNA/HBsAg levels, low platelet counts, and liver health is crucial for identifying patients at risk for LLV during treatment.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!